ADC Therapeutics SA (NYSE:ADCT) Receives $7.33 Average Target Price from Analysts

ADC Therapeutics SA (NYSE:ADCT) has been given an average recommendation of “Moderate Buy” by the four brokerages that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating and three have issued a buy rating on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $7.3333.

A number of research firms recently weighed in on ADCT. Royal Bank Of Canada reissued an “outperform” rating and set a $5.00 price target on shares of ADC Therapeutics in a research note on Wednesday, December 3rd. Guggenheim reaffirmed a “buy” rating and issued a $10.00 price objective on shares of ADC Therapeutics in a research note on Wednesday, November 12th. Wall Street Zen raised shares of ADC Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of ADC Therapeutics in a research note on Wednesday, January 21st.

Institutional Investors Weigh In On ADC Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. AQR Capital Management LLC lifted its stake in ADC Therapeutics by 411.1% in the first quarter. AQR Capital Management LLC now owns 201,170 shares of the company’s stock valued at $284,000 after buying an additional 161,808 shares during the period. Creative Planning acquired a new stake in shares of ADC Therapeutics in the 2nd quarter valued at approximately $96,000. Panagora Asset Management Inc. raised its position in shares of ADC Therapeutics by 400.8% in the 2nd quarter. Panagora Asset Management Inc. now owns 271,359 shares of the company’s stock valued at $727,000 after acquiring an additional 217,173 shares during the period. Stempoint Capital LP bought a new position in ADC Therapeutics during the 2nd quarter worth approximately $759,000. Finally, Nantahala Capital Management LLC bought a new position in ADC Therapeutics during the 2nd quarter worth approximately $6,074,000. Institutional investors own 41.10% of the company’s stock.

ADC Therapeutics Trading Down 1.8%

Shares of NYSE:ADCT opened at $4.12 on Wednesday. ADC Therapeutics has a 1-year low of $1.05 and a 1-year high of $4.80. The stock has a market capitalization of $509.77 million, a P/E ratio of -2.84 and a beta of 1.92. The business has a 50-day moving average price of $3.85 and a two-hundred day moving average price of $3.84.

About ADC Therapeutics

ADC Therapeutics SA is a clinical-stage biopharmaceutical company focused on the discovery and development of highly targeted antibody-drug conjugates (ADCs) designed to treat hematological malignancies such as non-Hodgkin lymphoma and acute myeloid leukemia. By marrying the specificity of monoclonal antibodies with potent cytotoxic payloads, the company aims to maximize tumor cell eradication while limiting off-target toxicity.

At the core of ADC Therapeutics’ portfolio is loncastuximab tesirine-lpyl, a CD19-directed ADC that received accelerated approval from the U.S.